Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021
21. Mai 2021 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit
20. Mai 2021 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
05. Mai 2021 16:01 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome
04. Mai 2021 08:00 ET
|
Soleno Therapeutics
Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR Data Presented in a Poster at the Pediatric Academic Societies Annual Meeting REDWOOD CITY, Calif., May 04,...
Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall
14. April 2021 20:40 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference
09. März 2021 16:01 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
08. März 2021 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
03. März 2021 16:01 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases
23. Februar 2021 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome
05. Februar 2021 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...